The General information section has been completely reviewed and updated, and includes new information about tablet technologies that are not suitable for crushing, and the size of tablets and capsules as a potential choking risk.

Extensive dispersion testing of more than 60 gastrointestinal medicines, including testing for suitability of administration into size 8 French enteral feeding tubes.

Monograph review and updates (141):

• gastrointestinal medicines, including new dispersion data and updated Comparative information for proton pump inhibitors
• cancer therapies
• electrolytes
• chelators and binders
• enzyme replacement therapies
• ivacaftor (and combinations)

New monographs (7):

• aluminium hydroxide
• Orkambi
• ritlecitinib
• selumetinib
• Symdeko
• tepotinib
• Trikafta

Monographs with significant changes (24):

• Balsalazide (dispersion data)
• Dabrafenib (formulation, administration)
• Entrectinib (administration)
• Esomeprazole (dispersion data)
• Gilteritinib (administration)
• Lansoprazole (dispersion data)
• Lenvatinib (administration)
• Mebeverine (dispersion data)
• Mesalazine (dispersion data)
• Metoclopramide (dispersion data)
• Midostaurin (compounded suspension)
• Nintedanib (administration)
• Nizatidine (dispersion data)
• Obeticholic acid (dispersion data)
• Omeprazole (formulation)
• Pantoprazole (dispersion data)
• Patiromer sobitex calcium (administration)
• Pomalidomide (administration)
• Ruxolitinib (compounded suspension)
• Sotorasib (administration)
• Trametinib (formulation)
• Ursodeoxycholic acid (dispersion data)
• Vemurafenib (administration)
• Vorinostat (hazard classification)

June 2025

Neurology 

Analgesics 

Immunosuppressants 

September 2025

Cardiovascular 

December 2025

Antimicrobials

March 2026

Mental health

June 2026

Genitourinary

Gynaecological

Hormones & Corticosteroids

September 2026

Diabetes

Rheumatology

December 2026

Antihistamines

Respiratory

Vaccines

Thyroid & bone

Vitamins and supplements